Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Oncology Center Of Excellence Coming, Moonshot Or Not

This article was originally published in The Pink Sheet Daily

Executive Summary

Commissioner Califf says review staff reorganization based on disease will go ahead regardless of what other headway VP Biden's initiative makes.


Related Content

FDA's Oncology Center Of Excellence On Equal Terms With CDER In New Org Chart
Multiple ‘Centers of Excellence’ At FDA Could Create Review Inefficiencies – Jenkins
Multiple ‘Centers of Excellence’ At US FDA Could Create Review Inefficiencies – Jenkins
FDA's Pazdur To Retain Drug Approval Duties In Oncology Center Of Excellence
Putting The Pieces Together For Combo Products Oversight
Don't Rush To Reorganize FDA, McClellan Says
FDA Reorganization Advocates Seek Senate Boost For Disease-Oriented Structure
FDA Talent Hunt: Is Recruiting From Academia Better Than Industry?
Califf Supports Combo Products Pathway At Confirmation Hearing





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts